AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02592239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A warm ham and cheese sandwich and a 200 ml fruit juice
Study NCT01131377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: If ABGA is pH ≥ 7.43 \& HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip.
Study NCT01131377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: They will receive saline 50ml via IV q 24h.
Study NCT01748539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Study NCT01748539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00775632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
Study NCT00775632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate or cyclosporine and methotrexate
Description: One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
Study NCT02109484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 10mcg
Description: 10 mcg
Study NCT02109484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 30 mcg
Description: 30 mcg
Study NCT02109484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 Subunit Vaccine 60mcg
Description: 60 mcg
Study NCT02109484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01296672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5mg every day by mouth for 3 months
Study NCT01296672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every day by mouth for 3 months
Study NCT01464060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
Study NCT01464060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Study NCT04602871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath Biopsy
Description: Breath Biopsy sampling using the ReCIVA® Breath Sampler
Study NCT04602871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath Biopsy
Description: Breath Biopsy sampling using the ReCIVA® Breath Sampler
Study NCT03742752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: administration of enteral nutrition
Study NCT03742752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition
Description: administration of parenteral nutrition
Study NCT02950467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: One individual oral psilocybin treatment session
Study NCT02950467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified brief Supportive Expressive Group Therapy
Description: Ten sessions of twice-weekly manualized group therapy
Study NCT02592057 — intervention group
Intervention type: DRUG
Intervention: SOF
Description: SOF tablets administered orally once daily based on approved prescribing information
Study NCT04248491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella chair
Description: Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
Study NCT04248491 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL Emsella chair
Description: Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
Study NCT01157221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a standardized physical therapy program
Description: passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
Study NCT01157221 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: a standardized physical therapy program
Description: passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
Study NCT01157221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMSMTA
Description: end-range mobilization/scapular mobilization treatment approach
Study NCT01445951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin with MedTone C Inhaler
Description: Inhalation Powder and injectable insulin
Study NCT01445951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere ®Insulin with Gen2 Inhaler
Description: Inhalation Powder and injectable insulin
Study NCT01445951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart in combination with a basal insulin
Description: Injectable insulin
Study NCT03020732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: test groups
Description: Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
Study NCT03020732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control groups
Description: Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
Study NCT02972073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
Study NCT03557892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM+CSII
Description: Animas Vibe Platinum insulin pump and Dexcom G4 CGM
Study NCT03557892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MDI with degludec
Description: Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
Study NCT01271283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01271283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally
Study NCT02342002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone for treatment of missed abortion
Study NCT02342002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol for treatment of missed abortion
Study NCT02342002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol for treatment of missed abortion
Study NCT03658486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
Study NCT02014636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
Study NCT02014636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
Study NCT02487420 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: shorter or longer period of specific dietary restrictions
Description: step by step gradual introduction of egg containing food products
Study NCT00336453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection
Study NCT03928977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Description: fMRI sequences done with motor paradigm (right and left arm), followed by resting state acquisition
Study NCT00336453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection
Study NCT00336453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.25mL dose for intramuscular injection
Study NCT00336453 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: 0.25mL dose for intramuscular injection
Study NCT03233555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive brochure
Study NCT03233555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Have access to EXCELS
Study NCT03233555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03233555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03233555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03233555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03233555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive quarterly calls
Study NCT01499277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: IV ceftaroline 600mg every 8 hours
Study NCT01499277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: IV vancomycin 15mg/kg every 12 hours
Study NCT03009266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
Study NCT00558870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain.
Study NCT00558870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.
Study NCT02175732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'KnowIt'
Description: Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine.
Study NCT01499277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: IV aztreonam 1 g every 8 hours
Study NCT02175732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'OnTrack'
Description: Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine.
Study NCT05193110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis
Description: Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital \& milling technology
Study NCT02364089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical removal of the adrenal tumor
Study NCT02364089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized medical treatment of hypertension by SAHR
Description: Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day.
Study NCT03456921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End-of-life conversation game called Hello
Description: To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
Study NCT04540042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelK2 (Part 1)
Description: I.V., multiple-dose (Day 1 and Day 22)
Study NCT04540042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: I.V., multiple-dose (Day 1 and Day 22)
Study NCT04540042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelK2 (Part 2)
Description: I.V., single-dose (Day 1)
Study NCT04540042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: I.V., single-dose (Day 1)
Study NCT03651284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aim2Be app with Live Coach + Fitbit + BMI tracking tools
Description: Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
Study NCT03651284 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
Description: Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
Study NCT02284282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal injection bupivacaine/morphine
Description: Spinal injection bupivacaine/morphine in laparoscopic surgery
Study NCT02284282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: subcutaneum injection lidocaine
Description: placebo injection
Study NCT04294719 — intervention group
Intervention type: OTHER
Intervention: Cognitive Adaptation Training (CAT)
Description: Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
Study NCT00779376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine 300mg tablets
Study NCT00779376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine 300mg tablets
Study NCT01539590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB3
Description: Daily intravenous administration of 2 mg/kg BB3 for four (4) days
Study NCT01539590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
Study NCT02639585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclinza and Sunvepra
Description: direct acting antiviral agent against to hepatitis C virus
Study NCT01743911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Sugar pills: 20mg orally, once a day for 2 weeks
Study NCT01743911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil pills: 20mg orally, once a day for 2 weeks.
Study NCT01849471 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
Study NCT02788747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg elamipretide
Description: Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
Study NCT02788747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg elamipretide
Description: Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days